Archazolid B was combined with the HMGCR inhibitor fluvastatin, and the cholesterol contents and cell viability of human bladder cancer T24 cells were decreased by approximately 20% compared to archazolid B treatment alone [28]. Here, HMGCR is linked to urinary bladder cancer.